SNNA Sienna Biopharmaceuticals Inc.

0.17
-0.01  -8%
Previous Close 0.18
Open 0.18
Price To Book 0.19
Market Cap 5,152,287
Shares 30,907,542
Volume 3,983,092
Short Ratio
Av. Daily Volume 995,681

NewsSee all news

  1. Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding

    WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met non-inferiority primary endpoint - February 8, 2019. Seeking partner for further advancement.
SNA-001
Reduction of light-pigmented hair
Phase 3 data released July 30, 2018 did not meet primary endpoint.
SNA-001
Acne
Phase 2b trial did not meet primary endpoint. Phase 3 trial to be initiated 2H 2019.
SNA-120
Pruritus associated with psoriasis
Phase 1/2 data released August 27, 2018.
SNA-125
Psoriasis
Phase 2 trial planned.
SNA-125
Atopic dermatitis

Latest News

  1. Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding

    WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition